Actively Recruiting
Neoadjuvant Therapy Using Drug Screening in Lab-grown Tumor Clusters for HER2 Positive Early Breast Cancer Patients
Led by Peking University People's Hospital · Updated on 2021-04-01
46
Participants Needed
1
Research Sites
235 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying a new method to guide neoadjuvant therapy for women with HER2-positive early breast cancer. This study focuses on using drug sensitivity screening based on patient-derived tumor-like cell clusters PTC grown in the lab. The goal is to find out if this screening can help select effective chemotherapy drugs and possibly reduce the amount of chemotherapy needed, while maintaining good treatment results like pathological complete response pCR. Participants will all receive targeted therapy with trastuzumab and pertuzumab. The chemotherapy drugs given will be chosen based on the results of the PTC drug sensitivity screening. If a single chemotherapy drug shows effectiveness in the lab test, it will be used as the treatment. This personalized approach aims to achieve a pCR rate of about 60%, similar to current standards but with less chemotherapy. The study includes only one treatment group receiving this tailored neoadjuvant therapy. During the study, participants will be monitored for pathological complete response within 12 weeks after treatment starts. Long-term outcomes like event-free survival and invasive disease-free survival will be followed for up to five years. Researchers will also track tumor response rates. Breast cancer tissue samples will be used for the lab-based drug screening, and clinical assessments will be done regularly to evaluate treatment effects and safety. The total study duration includes initial treatment and extended follow-up for survival outcomes.
CONDITIONS
Brief Title
Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for HER2 Positive Early Breast Cancer Patients
Research Team
C
Chaobin Wang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here